AI Terminal

MODULE: AI_ANALYST

Interactive Q&A, Risk Assessment, Summarization

MODULE: DATA_EXTRACT

Excel Export, XBRL Parsing, Table Digitization

MODULE: PEER_COMP

Sector Benchmarking, Sentiment Analysis

SYSTEM ACCESS LOCKED

Authenticate / Register Log In

Medistim

Earnings Release • Apr 25, 2023

3662_rns_2023-04-25_53fdc3b9-8ded-4671-9d21-00c65aeb885d.html

Earnings Release

Open in Viewer

Opens in native device viewer

FIRST QUARTER FINANCIAL RESULTS 2023

Sales for the first quarter ended at MNOK 129.3 (MNOK 116.1), an increase of 11.3%. The Vascular business segment continues the positive development and grows at 21.5% in NOK, currency neutral 8.8% growth. The Imaging products grow at 9.4% in NOK with a currency neutral decline of 3.7%. Currency neutral growth of own products was 2.5%. Operating profit (EBIT) for the quarter ended at MNOK 33.5 (MNOK 33.4). Medistim establishes direct sales organizations in both Canada and China this quarter. Cash position is down MNOK 3.3 due to inventory build up and timing of sales for the quarter. The General Meeting decided a dividend of NOK 4.50 per share, a total dividend payment of MNOK 82.2